$37.53
1.16% yesterday
Nasdaq, Sep 03, 10:18 pm CET

Harmony Biosciences Holdings Stock price

$37.53
+1.99 5.60% 1M
+5.35 16.63% 6M
+3.12 9.07% YTD
+1.18 3.25% 1Y
-6.83 15.40% 3Y
-2.86 7.08% 5Y
+0.52 1.41% 10Y
+0.52 1.41% 20Y
Nasdaq, Closing price Wed, Sep 03 2025
+0.43 1.16%

Key metrics

Basic
Market capitalization
$2.1b
Enterprise Value
$1.7b
Net debt
positive
Cash
$565.3m
Shares outstanding
57.5m
Valuation (TTM | estimate)
P/E
12.0 | 11.6
P/S
2.8 | 2.5
EV/Sales
2.3 | 2.0
EV/FCF
6.7
P/B
2.8
Financial Health
Equity Ratio
66.0%
Return on Equity
22.1%
ROCE
23.9%
ROIC
34.8%
Debt/Equity
0.2
Financials (TTM | estimate)
Revenue
$772.5m | $858.3m
EBITDA
$245.7m | $301.2m
EBIT
$221.9m | $249.5m
Net Income
$180.9m | $184.5m
Free Cash Flow
$258.5m
Growth (TTM | estimate)
Revenue
17.7% | 20.1%
EBITDA
18.9% | 40.3%
EBIT
14.0% | 30.7%
Net Income
57.2% | 26.8%
Free Cash Flow
21.3%
Margin (TTM | estimate)
Gross
78.3%
EBITDA
31.8% | 35.1%
EBIT
28.7%
Net
23.4% | 21.5%
Free Cash Flow
33.5%
More
EPS
$3.1
FCF per Share
$4.5
Short interest
16.3%
Employees
268
Rev per Employee
$2.7m
Show more

Is Harmony Biosciences Holdings a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

Harmony Biosciences Holdings Stock Analysis

Unlock Scores for Free

Analyst Opinions

17 Analysts have issued a Harmony Biosciences Holdings forecast:

14x Buy
82%
2x Hold
12%
1x Sell
6%

Analyst Opinions

17 Analysts have issued a Harmony Biosciences Holdings forecast:

Buy
82%
Hold
12%
Sell
6%

Financial data from Harmony Biosciences Holdings

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
773 773
18% 18%
100%
- Direct Costs 167 167
24% 24%
22%
605 605
16% 16%
78%
- Selling and Administrative Expenses 215 215
9% 9%
28%
- Research and Development Expense 145 145
24% 24%
19%
246 246
19% 19%
32%
- Depreciation and Amortization 24 24
100% 100%
3%
EBIT (Operating Income) EBIT 222 222
14% 14%
29%
Net Profit 181 181
57% 57%
23%

In millions USD.

Don't miss a Thing! We will send you all news about Harmony Biosciences Holdings directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Harmony Biosciences Holdings Stock News

Neutral
Business Wire
9 days ago
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that it will present data from its rare epilepsy pipeline at the 36th International Epilepsy Congress (IEC) being held August 30 – September 3, 2025, at the Lisbon Congress Centre in Lisbon, Portugal. Poster presentations will highlight information from the company's investigation of EPX-1...
Neutral
Business Wire
14 days ago
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the 2025 Cantor Global Healthcare Conference in New York, N.Y., on Thursday, September 4, 2025, at 2:10 p.m. ET. A webcast of the fireside chat will be available on the investor page of the Harmony Biosciences website at...
Positive
Seeking Alpha
14 days ago
Harmony Biosciences remains a Buy due to strong Wakix growth, profitability, and undervalued metrics despite recent setbacks. Upcoming catalysts—especially ZYN002 Phase 3 data in Fragile X—could drive significant upside, with >25% share price potential if successful, in my view. Pipeline diversification (pitolisant HD, GI, OX2R agonist, EPX-100) aims to offset Wakix patent expiry and expand lon...
More Harmony Biosciences Holdings News

Company Profile

Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company, which engages in the development and commercialization of therapies for the treatment of neurological disorders. Its product WAKIX is a molecule with a novel mechanism of action designed to increase histamine signaling in the brain by binding to H3 receptors. The company was founded on July 25, 2017 and is headquartered in Plymouth Meeting, PA.

Head office United States
CEO Jeffrey Dayno
Employees 268
Founded 2017
Website www.harmonybiosciences.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today